SCHEMBL4119254

SCHEMBL4119254

O=C(C#Cc1ccc(F)cc1F)N1CCc2ccccc2C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
KMT2A Q03164 3/20 0.51
PDE4B Q07343 3/20 0.51
PDE4D Q08499 2/20 0.51
NPC1 O15118 5/20 0.49
RAB9A P51151 4/20 0.49
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
MEN1 O00255 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NOTUM Q6P988 1/20 0.46
GPR183 P32249 1/20 0.45
MAPT P10636 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
GRM5 P41594 2/20 0.43
TMPRSS2 O15393 1/20 0.43
HTR1A P08908 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118067 0.87 NPC1 (0.53) ALDH1A1HPGDSMN1; SMN2KMT2APDE4B
SCHEMBL4105991 0.82 NPC1 (0.56) ALDH1A1HPGDSMN1; SMN2KMT2APDE4B
SCHEMBL4118301 0.78 TAS1R3 (0.57) ALDH1A1HPGDSMN1; SMN2KMT2ANPC1
SCHEMBL4124894 0.77 TAS1R3 (0.60) ALDH1A1HPGDSMN1; SMN2KMT2ANPC1
SCHEMBL4105545 0.76 GRM5 (0.54) ALDH1A1HPGDSMN1; SMN2KMT2ANPC1
SCHEMBL4113675 0.76 GRM5 (0.54) ALDH1A1HPGDSMN1; SMN2KMT2ANPC1
SCHEMBL4116705 0.76 NOTUM (0.55) ALDH1A1HPGDSMN1; SMN2KMT2APDE4B
SCHEMBL4115831 0.74 RAB9A (0.56) ALDH1A1HPGDSMN1; SMN2KMT2ANPC1
SCHEMBL4110501 0.73 RAB9A (0.57) ALDH1A1HPGDSMN1; SMN2KMT2ANPC1
SCHEMBL4119251 0.72 HTR1A (0.46) ALDH1A1KMT2AHTR1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US claimed
EP-1968938-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP claimed
WO-2007079957-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO claimed
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US disclosed
EP-1968938-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP disclosed
WO-2007079957-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS PCCA, PPARA, PTGES ALDH1A1 360/4885HPGD 64/4885SMN1; SMN2 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.